April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

BMS combo meets in Phase III for malignant pleural mesothelioma
Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4 mAb Yervoy ipilimumab met the primary endpoint of improving overall survival compared with Alimta pemetrexed plus platinum-based chemotherapy as first-line treatment of malignant pleural mesothelioma.

Idorsia’s daridorexant meets in Phase III for insomnia
Top-line Phase III results from Idorsia Ltd. (SIX:IDIA) have shown two doses of daridorexant (ACT-541468) met the primary endpoints of improved sleep onset and sleep maintenance in insomnia patients. The company expects to report data from another Phase III trial of the OX1R/OX2R dual antagonist for insomnia in 3Q20. Idorsia shares gained CHF3.64 (14%) to CHF30.22 on the Swiss Exchange Monday. ...